Debbie Rigby rounds up the latest research news that matters to pharmacy
The Azithromycin Against Placebo in Exacerbations of Asthma (AZALEA) randomized, double-blind, placebo-controlled clinical trial, a United Kingdom–based multicenter study in adults has concluded that azithromycin treatment resulted in no statistically or clinically significant benefit in quality-of-life questionnaires or lung function. Adults with a history of asthma for more than six months were treated with azithromycin 500 mg daily or matched placebo for three days.
JAMA Intern Med. Published online September 19, 2016.
A systematic review of 23 randomized, controlled trials (n=3494) has concluded that isoflavones probably have beneficial effects on bone health in menopausal women and that supplementation with a phytoestrogen can probably prevent the reduction in BMD and maintain a healthy bone structure during menopause. Different types of soy isoflavone extracts, including genistein extracts (either alone or in combination with daidzein), dietary products containing different amounts of phytoestrogens, and red clover extracts were used in the designed interventions.
Climacteric. Published online: 06 Oct 2016
Analysis of US claims data (n=45,361) has shown that among newly anticoagulated NVAF patients apixaban and dabigatran initiation was associated with significantly lower risk of major bleeding compared to warfarin initiation. There was no significant difference in risk of major bleeding between matched rivaroxaban and warfarin initiators. When compared to apixaban, rivaroxaban initiation was associated with significantly higher risk of major bleeding.
Thromb Haemost 2016; 116:
A prospective cohort study of U.S. women participating in the Women’s Health Study concluded that consumption of fish and long-chain omega-3 polyunsaturated fatty acids (PUFAs) does not reduce the risk of major CVD among healthy postmenopausal women.
Am J Prev Med 2016